Delving into the Latest Updates on Trandolapril with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Gopten, Nortensin, Odrik

+ [9]

Target

ACE

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization

Nippon Shinyaku Co., Ltd.

Active Organization

Nippon Shinyaku Co., Ltd.

Inactive Organization

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (31 Jan 1996),

Hypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H34N2O5

InChIKeyVXFJYXUZANRPDJ-WTNASJBWSA-N

CAS Registry87679-37-6

Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

Start Date01 Jun 2015

Sponsor / Collaborator

University of Nebraska

CTR20132857

/ RecruitingNot Applicable

群多普利胶囊用于高血压治疗的有效性及安全性的多中心、随机、双盲双模拟、阳性药对照临床试验

[Translation] A multicenter, randomized, double-blind, double-dummy, active-controlled clinical trial on the efficacy and safety of trandolapril capsules in the treatment of hypertension

评价群多普利胶囊用于高血压治疗的有效性与安全性

[Translation]

To evaluate the efficacy and safety of trandolapril capsules in the treatment of hypertension

Start Date06 Mar 2014

Sponsor / Collaborator

DDLD (Beijing) Pharmaceutical Technology Co., Ltd.

CTR20132838

/ CompletedNot Applicable

群多普利（ Trandolapril）胶囊健康人体空腹状态下三剂量（1 mg、2 mg及4 mg）单次及单剂量（ 2 mg）多次口服给药代动力学研究

[Translation] Study on the kinetics of Trandolapril capsules after single oral administration of three doses (1 mg, 2 mg and 4 mg) and single dose (2 mg) in healthy volunteers under fasting state

评估群多普利胶囊健康人体空腹状态下三剂量（1 mg、2 mg及4 mg）单次及单剂量（2 mg）多次口服给药药代动力学特征

[Translation]

To evaluate the pharmacokinetic characteristics of single oral administration of three doses (1 mg, 2 mg and 4 mg) and single dose (2 mg) of trandolapril capsules in healthy volunteers under fasting state

Start Date12 Jul 2013

Sponsor / Collaborator

DDLD (Beijing) Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Trandolapril

Login to view more data

100 Translational Medicine associated with Trandolapril

Login to view more data

100 Patents (Medical) associated with Trandolapril

Login to view more data

857

Literatures (Medical) associated with Trandolapril

28 Nov 2024·JOURNAL OF MEDICINAL CHEMISTRY

Proline Analogues in Drug Design: Current Trends and Future Prospects

Review

Author: Mykhailiuk, Pavel K. ; Kubyshkin, Vladimir

Proline analogues are versatile chemical building blocks that enable modular construction of small-molecule drugs and pharmaceutical peptides. Over the past 15 years, the FDA has approved over 15 drugs containing proline analogues in their structures, five in the last three years alone (daridorexant, trofinetide, nirmatrelvir, rezafungin, danicopan). This perspective offers an analysis of the most common types of proline analogues currently trending in drug design. We focus on examples of fluoroprolines, α-methylproline, bicyclic proline analogues, and aminoprolines, while also highlighting proline analogues that remain underrepresented. We supplement our analysis with physicochemical information regarding the specific molecular properties of these moieties. Additionally, we discuss several intriguing cases where nonproline residues were replaced with proline analogues as a strategy to eliminate unwanted hydrogen bond donor sites. In conclusion, we present some suggestions for the future exploration of this promising class of molecular entities in drug discovery.

01 Nov 2024·Clinical Case Reports

Hypertensive Encephalopathy Triggered by Indomethacin Use

Article

Author: Wu, Peter E. ; Raco, Vanessa ; Plitman, Jane

ABSTRACT:

We present the case of a man in his 70s who developed acute confusion from hypertensive encephalopathy triggered by indomethacin. He was recently prescribed indomethacin, a non‐steroidal anti‐inflammatory drug (NSAID) for headaches. However, his headaches were in the context of worsening hypertension that was treated with trandolapril. The use of indomethacin consequently worsened his underlying condition. On presentation to the emergency department, his blood pressure was 190/110 mmHg. Bloodwork including electrolytes, glucose, metabolic studies, renal and liver function were within normal limits; infectious workup including blood and urine cultures subsequently returned negative; and brain computed tomography and magnetic resonance imaging revealed no acute process to explain his presentation. Indomethacin was discontinued and the patient's hypertension was treated with amlodipine. Both his confusion and underlying headaches resolved as his blood pressure normalized. The patient was diagnosed with hypertensive encephalopathy triggered by indomethacin. NSAID use can trigger blood pressure decompensation, especially in patients with underlying hypertension; this effect is particularly pronounced in patients treated with anti‐hypertensive medications that inhibit the renin‐angiotensin‐aldosterone (RAS) system. Symptomatic treatment with NSAIDs is not without potential harm; it is important to carefully consider a patient's underlying diagnosis, indication for therapy and risk for adverse effects.

01 Aug 2024·Data in Brief

Dataset for discovering new hypertension small molecules using machine learning-aided computational fragment-based design

Article

Author: Lehasa, Odifentse Mapula-e ; Chude-Okonkwo, Uche A. K.

This dataset demonstrates the use of computational fragmentation-based and machine learning-aided drug discovery to generate new lead molecules for the treatment of hypertension. Specifically, the focus is on agents targeting the renin-angiotensin-aldosterone system (RAAS), commonly classified as Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs). The preliminary dataset was a target-specific, user-generated fragment library of 63 molecular fragments of the 26 approved ACEI and ARB molecules obtained from the ChEMBL and DrugBank molecular databases. This fragment library provided the primary input dataset to generate the new lead molecules presented in the dataset. The newly generated molecules were screened to check whether they met the criteria for oral drugs and comprised the ACEI or ARB core functional group criterion. Using unsupervised machine learning, the molecules that met the criterion were divided into clusters of drug classes based on their functional group allocation. This process led to three final output datasets, one containing the new ACEI molecules, another for the new ARB molecules, and the last for the new unassigned class molecules. This data can aid in the timely and efficient design of novel antihypertensive drugs. It can also be used in precision hypertension medicine for patients with treatment resistance, non-response or co-morbidities. Although this dataset is specific to antihypertensive agents, the model can be reused with minimal changes to produce new lead molecules for other health conditions.

2

News (Medical) associated with Trandolapril

01 Sep 2023

·www.fiercepharma.com

Fierce Pharma Asia—Vyvanse generics; Lenvima's trial flop; Adagene's ADC breakup

FDA approvals for Vyvanse generics, a Keytruda-Lenvima clinical trial flop and a dead deal between Adagene and ADC Therapeutics made our news this week. Generics to Takeda's blockbuster ADHD drug Vyvanse are now approved in the U.S. Merck and Eisai's Keytruda-Lenvima combo failed in another pivotal trial. ADC Therapeutics walked away from an antibody-drug conjugate partnership with Adagene. Plus more. 1. Amid shortage, FDA clears several generics of Takeda's popular ADHD drug Vyvanse The FDA has approved a slate of generics to Takeda’s ADHD drug Vyvanse. Teva, Sun Pharma, Actavis, Mylan and Hikma are among those that won the FDA’s blessing. The Takeda originator went into short supply a few weeks ago amid increased demand and a manufacturing hiccup. 2. Another Keytruda-Lenvima ambition is dashed as Merck, Eisai end head and neck cancer trial Merck and Eisai’s plan to combine Keytruda and Lenvima has suffered another setback. The companies decided to end a phase 3 trial in newly diagnosed PD-L1-positive head and neck cancer early. After reviewing interim data, they figured the combo likely won’t be able to outdo Keytruda alone at extending patients' lives. 3. ADC Therapeutics calls it quits on solid tumor collaboration with Adagene ADC Therapeutics has decided not to opt in on Chinese biotech Adagene’s antibody-drug conjugate program. The two teamed up in 2019 to combine Adagene’s antibody platform with ADC’s payload. ADC recently cut 17% of its workforce to save costs and to focus on FDA-approved Zynlonta and low-risk R&D projects. 4. Fujifilm Diosynth, planning for fast growth, reveals new structure and names unit leadership Fujifilm Diosynth Biotechnologies has reshaped its business structure. The company now has a large-scale strategic business unit headed by Kenneth Bilenberg in charge of the CDMO’s large facilities in Denmark and North Carolina supporting customers with large volume needs. Lee Kingsbury will oversee the company's small-scale production unit. 5. Glenmark, Baxter issue separate recalls for hypertension and cancer drugs Glenmark recalled 1,200 bottles of trandolapril and verapamil hydrochloride extended-release tablets produced at a site in India. The drugs are used to treat high blood pressure but were found to be subpotent in a three-month test. 6. Genexine's weekly growth hormone equal to Novo shot in phase 3, teeing up filing in China South Korean biotech Genexine said its once-weekly growth hormone, eftansomatropin alfa, matched Novo Nordisk’s daily Norditropin in a phase 3 trial in Chinese children with growth hormone deficiency. I-Mab, through its acquisition of Tasgen Biotech, owns rights to eftansomatropin alfa in China. 7. CanSino paused mRNA COVID vaccine development, looks for more CDMO deals (Reuters) China’s CanSino Biologics has paused development of mRNA COVID vaccines, co-founder and CEO Xuefeng Yu told Reuters. For its newly built mRNA facility in Shanghai, CanSino is now looking to manufacture vaccines for other companies, just as in its recent deal with AstraZeneca.

Phase 3VaccineClinical ResultDrug ApprovalmRNA

28 Aug 2023

·www.fiercepharma.com

Glenmark, Baxter issue separate recalls for hypertension and cancer drugs

Glenmark USA and Baxter Healthcare issue separate voluntary recalls for blood pressure tables and an injectable cancer drug, respectively. Glenmark Pharmaceuticals USA and Baxter Healthcare issued separate recalls citing out-of-specification tests and problems with labels for drugs used to treat hypertension and cancer, respectively. Both recalls are designated as Class III, meaning the products in question violate federal regulations but are unlikely to cause adverse health consequences. Glenmark recalled 1,200 bottles of trandolapril and verapamil hydrochloride extended-release tablets used to treat high blood pressure. In a notice, the company said an assay test at the three-month time point found the drug to be subpotent. The company produced the medicine at one of its sites in India. The tablets had been distributed nationwide in the U.S. Baxter, meanwhile, recently issued a voluntary recall for 13,502 vials of bendamustine HCl injection, which is used to treat cancers such as lymphoma and chronic lymphocytic leukemia. The drug is being recalled after a customer complaint flagged issues with labels falling off the vials. India-based Glenmark is no stranger to FDA scrutiny and recalls. Late last year, an FDA warning letter flagged issues with batch failures, lab controls, record-keeping and more at a site in Colvale, India. A separate assay test by the company had prompted a prior recall in June 2022. As for Baxter, the company recently sold its biopharma solutions unit to private equity firms Warburg Pincus and Advent International in a $4.25 billion deal. That standalone company just named a new CEO in Franco Negron.

100 Deals associated with Trandolapril

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00383	Trandolapril	C09AA10	DB00519

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	JP	Nippon Shinyaku Co., Ltd.	31 Jan 1996

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	gtyeiqazwg(qebpxbnmmc) = wtiwkxealw jjbhmjmxdy (edqsytpmdn, vdsnalfgqt - nqbndailkg) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	gtyeiqazwg(qebpxbnmmc) = xrcdxxwihh jjbhmjmxdy (edqsytpmdn, ikpqdrhive - qpmnhfjixx) View more
NCT00887510 (MEAD, CTgov)	Phase 4	Metabolic Syndrome \| Hypertension	24	Hydrochlorothiazide+Trandolapril (Thiazide First)	rudsgsufhl(pxpnavkoqx) = srunottwoz yeqgrarvpr (pmzltbqhqq, ajznafeegc - ritkcrqeta) View more	-	17 Jun 2014
				Hydrochlorothiazide+Trandolapril (Trandolapril First)	rudsgsufhl(pxpnavkoqx) = wkawxdtynr yeqgrarvpr (pmzltbqhqq, ewnggtslmc - dvejcaqlfa) View more
NCT00391846 (CTgov)	Phase 4	Heart Failure \| Left ventricular systolic dysfunction	252	The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Guided by NT-proBNP)	fheeykufif(dgjtorgrna) = dftmnyqptg jnzyctgjhj (itjfaevdqb, hqdwbxhqtw - pwebuefwwq) View more	-	18 Jun 2012
				The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Not Guided by NT-proBNP)	fheeykufif(dgjtorgrna) = liorzvjkic jnzyctgjhj (itjfaevdqb, cntuddzxja - czkkldjujo) View more
NCT00235014 (BENEDICT-B, Pubmed \| J Hypertens)	Phase 4	Diabetic Nephropathies \| Hypertension	281	Verapamil/trandolapril 180 mg/2 mg daily	qsapjxhodk(vacnjpemal): hazard ratio = 0.93 (95% CI, 0.5 - 1.72), P-Value = 0.816 View more	Negative	01 Feb 2011
				Trandolapril 2 mg daily
PP.24.468 (ESH2010)	Not Applicable	Non-diabetic Chronic Kidney Disease	14	Trandolapril 4 mg o.i.d. (8:00 a.m.)	rfqkdywlsw(euxlbrdlbp) = decreased significantly when trandolapril was administered b.i.d. or in the evening, with lowest ratio after evening dosing kmoqjgitga (ndnewpniyy ) View more	Positive	01 Jun 2010
NCT00840073 (CTgov)	Phase 1	-	50	Trandolapril 4 mg Tablets (Trandolapril)	isbcmgdhcj(zfszltpryc) = sbohniwaqe exztlzvafc (fvkdemfszm, srhhwepaaj - anrjiquvsw) View more	-	18 Aug 2009
				Mavik® 4 mg Tablets (Mavik®)	isbcmgdhcj(zfszltpryc) = nyxislqmnl exztlzvafc (fvkdemfszm, bvwflkrchl - neggiwgale) View more
NCT00840632 (CTgov)	Phase 1	-	40	Trandolapril 4 mg Tablets (Trandolapril)	cvljusgnyi(nngmwsvbjw) = dwioymesce kzcoenpcga (pdsymckryv, lukxvsvavr - xdclauzgrf) View more	-	18 Aug 2009
				Mavik® 4 mg Tablets (Mavik®)	cvljusgnyi(nngmwsvbjw) = sppjdruebb kzcoenpcga (pdsymckryv, tyownyorwh - mopxjmkptw) View more